Guardian Pharmacy Services, Inc. financial data

Symbol
GRDN on NYSE
Location
Atlanta, GA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 11 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 124% %
Quick Ratio 29% %
Return On Equity 26% %
Return On Assets 13% %
Operating Margin 5% %

Shares

Label TTM Value / Value Unit Change %
Entity Public Float $411,599,923 USD

Income Statement

Label TTM Value / Value Unit Change %
Revenues $1,448,685,000 USD 18%
Operating Income (Loss) $72,701,000 USD 84%
Nonoperating Income (Expense) $722,000 USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $73,423,000 USD 92%
Income Tax Expense (Benefit) $24,465,000 USD 437%
Net Income (Loss) Attributable to Parent $49,219,000 USD

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $65,619,000 USD 1308%
Accounts Receivable, after Allowance for Credit Loss, Current $101,614,000 USD 4.6%
Inventory, Net $43,359,000 USD 6.9%
Other Assets, Current $11,042,000 USD 15%
Assets, Current $221,634,000 USD 46%
Deferred Income Tax Assets, Net $2,199,000 USD -58%
Property, Plant and Equipment, Net $55,522,000 USD 11%
Operating Lease, Right-of-Use Asset $34,649,000 USD 19%
Intangible Assets, Net (Excluding Goodwill) $18,475,000 USD 24%
Goodwill $79,743,000 USD 15%
Other Assets, Noncurrent $436,000 USD 14%
Assets $412,658,000 USD 29%
Accounts Payable, Current $116,206,000 USD 13%
Employee-related Liabilities, Current $15,048,000 USD 4.3%
Liabilities, Current $160,703,000 USD 12%
Operating Lease, Liability, Noncurrent $29,992,000 USD 29%
Other Liabilities, Noncurrent $4,039,000 USD 18%
Liabilities $194,734,000 USD 14%
Retained Earnings (Accumulated Deficit) $66,343,000 USD 287%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $217,924,000 USD 45%
Liabilities and Equity $412,658,000 USD 29%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $17,550,000 USD 103%
Net Cash Provided by (Used in) Financing Activities $2,666,000 USD 53%
Net Cash Provided by (Used in) Investing Activities $5,545,000 USD -54%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $9,339,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $65,619,000 USD 1308%
Interest Paid, Excluding Capitalized Interest, Operating Activities $175,000 USD -77%
Deferred Tax Assets, Valuation Allowance $0 USD
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure
Deferred Tax Assets, Gross $20,317,000 USD 2.8%
Lessee, Operating Lease, Liability, to be Paid $42,787,000 USD
Property, Plant and Equipment, Gross $143,367,000 USD 12%
Operating Lease, Liability, Current $7,150,000 USD 4.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two $9,220,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $8,963,000 USD
Operating Lease, Weighted Average Discount Rate, Percent 0.0567 pure 2.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three $8,498,000 USD
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $7,691,000 USD
Additional Paid in Capital $139,353,000 USD 11%
Depreciation, Depletion and Amortization $5,267,000 USD 11%
Deferred Tax Assets, Net of Valuation Allowance $20,317,000 USD 2.8%
Share-based Payment Arrangement, Expense $13,850,000 USD -89%